Clinical trial · Interventional
Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only
Digital Monitoring With Patient-Reported Outcomes in Cancer Care: A Randomized Controlled Trial RC - 102 (Resilience Care - 102)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn if Resilience PRO, a digital solution performing remote symptoms monitoring, can improve the quality of life of patients with a diagnosis of cancer receiving systemic anticancer treatment. The main question it aims to answer is: \- Do patients with a diagnosis of cancer receiving systemic anticancer therapy and using Resilience PRO have an improved quality of life? Researchers will compare patients using Resilience PRO plus care as usual to patients receiving care as usual only. Participants in the intervention arm will use Resilience PRO, a mobile phone application regularly asking participants about their symptoms. For clinically important symptoms, an alert is sent to the care team that can incorporate that information to timely adjust the care of the participants. Participants both in the control arm and in the intervention arm will further receive care as usual.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Resilience PRO | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Remote Symptoms Monitoring with Resilience PRO
- description
- Resilience PRO will be added on top of conventional care
- interventionNames
- Device: Resilience PRO
- type
- NO_INTERVENTION
- label
- Usual care without Remote Symptoms Monitoring
- description
- Conventional care only
Primary outcomes (1)
- measure
- Health-Related quality of life
- timeFrame
- 3 months
- description
- EORTC QLQ-C30
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age: Adults ≥ 18 years. * Informed Consent: Patient giving signed informed consent to participate in the RC - 102 clinical study. * Diagnosis: Patients with cancer at any stage. * Systemic Treatment * Remote Monitoring Eligibility: Access to a smartphone * Language: Ability to understand and communicate in the language(s) in which the trial is conducted. Exclusion Criteria: * Age: Patients under 18 years of age. * Life Expectancy: Patients with a life expectancy of less than 6 months as estimated by the treating physician. * Concurrent remote monitoring * HSCT or CAR-T Therapy * Cognitive Impairment * Pregnancy or breastfeeding * Subject under administrative or judicial control
References
Publications (0)
Data not yet available